In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Henry S PanDepartment of Pharmaceutical Chemistry, The Cardiovascular Research Institution, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1323-037X Gregory E MerzInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0842-4935 Alissa Nana LiWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3474-8044 Minh Quan LeInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0002-4382-6526 Hyunil JoDepartment of Pharmaceutical Chemistry, The Cardiovascular Research Institution, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4863-0779 Athena QuddusInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Anthony YungInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Rian C KormosDepartment of Pharmaceutical Chemistry, The Cardiovascular Research Institution, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5831-1464 Arthur A MeloInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9345-1462 Eliana Marisa RamosDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0009-0003-7982-4415 Argentina Lario LagoWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Salvatore SpinaWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3570-9143 Lea T GrinbergWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6809-0618 Howard J RosenWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9281-7402 Eric TseInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2082-9006 Maria Luisa Gorno-TempiniWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7426-7782 William F DeGradoDepartment of Pharmaceutical Chemistry, The Cardiovascular Research Institution, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4745-263X William W SeeleyWeill Institute for Neurosciences, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1410-2027 Daniel R SouthworthInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7108-9389 Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Adam Mark Staffaroni · 2019 to 2026
$120.9MNational Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MEarly Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MVIRAL DEGENERATIVE DEMENTING DISEASE IN AGING (SUPP)P01AG002132 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 1985 to 2024
$51.7MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9MLongitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9MTraining - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4MNIA NIH HHS P01 AG002132NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS U01 AG045390NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NINDS NIH HHS U54 NS092089
6 · The paper itselfAbstract
Frontotemporal lobar degeneration with tau inclusions (FTLD-tau) comprise a class of fatal heterogeneous neurodegenerative diseases. Approximately 10% arise from pathogenic MAPT mutations and often cause severe, early-onset disease with pathology that is distinct yet partially overlapping with sporadic cases. Here, we evaluated post-mortem tissue from a patient with FTLD-tau due to
Identifiers
PMID41726928
PMCPMC12918850
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390